Who are Lamiduvine (Epivir)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abacavir/lamivudine/zidovudine, Emtricitabine / Tenofovir, Lamivudine/Zidovudine, Doravirine + tenofovir DF + lamivudine, Atazanavir/ Stavidine / Lamivudine, Reyataz + Epzicom.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lamiduvine-epivir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lamiduvine (Epivir) — Competitive Intelligence Brief

Lamiduvine (Epivir) (Lamiduvine (Epivir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside Reverse Transcriptase Inhibitor (NRTI). Area: Metabolic.

marketed Nucleoside Reverse Transcriptase Inhibitor (NRTI) HIV reverse transcriptase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Lamiduvine (Epivir) (Lamiduvine (Epivir)) — Catholic University of the Sacred Heart. Lamiduvine inhibits the HIV reverse transcriptase enzyme, preventing viral RNA from being converted into DNA, thus halting viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lamiduvine (Epivir) TARGET	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase
Abacavir/lamivudine/zidovudine	Abacavir/lamivudine/zidovudine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Emtricitabine / Tenofovir	Emtricitabine / Tenofovir	The Miriam Hospital	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Lamivudine/Zidovudine	Lamivudine/Zidovudine	Bristol-Myers Squibb	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Doravirine + tenofovir DF + lamivudine	Doravirine + tenofovir DF + lamivudine	Instituto Mexicano del Seguro Social	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside Reverse Transcriptase Inhibitor (NRTI) class)

Catholic University of the Sacred Heart · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lamiduvine (Epivir) — Competitive Intelligence Brief. https://druglandscape.com/ci/lamiduvine-epivir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab